Big Pharma tested oral cannabis spray for brain tumors in a new study

Medical studies are reportedly due to begin at the University of Leeds on the use of a medicinal cannabis drug called Sativex to treat brain tumors. Sativex is used together with temozolomide, a recognized chemotherapy treatment. Hope rests on the drug’s ability to kill a significant amount of cancer cells during the trials.

In England, an average of 2,200 people are diagnosed with the condition known as glioblastoma. Medical experts claim that it is one of the most common forms of brain tumors seen in the UK.

This condition is very aggressive and results in a high mortality rate in patients. Glioblastoma is a tumor that has a 70% chance of recurring despite being treated with surgical procedures, radiation therapy, and chemotherapy sessions.

Glioblastoma is currently more or less a death sentence. If detected early, patients have to live about 12-18 months. However, those with recurrent illnesses have 10 months or less to live.

The drug called Sativex

This medication is a cannabis-based oral spray. This is not the first time Sativex has been used in a medical study. It has been proven effective in treating conditions such as multiple sclerosis. The multiple sclerosis study was successful and Sativex is now being given to patients with muscle stiffness and cramps to reduce their spasticity.

The NHS approves the use of cannabis drugs; Sativex and Epidyolex in the treatment of diseases. Sativex was first approved in 2014 and cost around £ 2,000 per patient.

The oral drug Sativex contains the two main cannabinoids in equal amounts. The presence of both delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) creates therapeutic effects that reduce inflammation, anxiety, and pain. It is important to note that the drugs do not produce psychoactive effects when consumed.

Can Sativex be used to treat glioblastoma?

Everyone is concerned with this question. In order to be able to answer this question, the clinical studies must be completed. The University of Leeds is the first researcher in the world to consider the use of Sativex to treat brain tumors.

Susan Short, one of the researchers involved in this study, said the team believes Sativex may be the missing piece in the medical puzzle for treating glioblastoma. Short, who is a professor of clinical oncology and neuro-oncology, claims that Sativex may be able to kill the tumor cells if given along with chemotherapy containing temozolomide.

The team believes that these individual drugs are most effective when used together. Sativex is expected to potentiate the growth inhibiting effects of chemotherapy against glioblastoma tumors. The slower the growth rate of the tumor cells, the longer the patient had to live.

The researchers are being supported in this clinical investigation by cancer charities and the NHS. The results of this study will determine whether the lives of glioblastoma patients can be significantly extended by using the cannabis-based oral spray.

One of the charities, The Brain Tumor Charity, is set to fund the study. As of January 2022, the organization will begin recruiting patients from 15 different hospitals recognized by the National Health Services across the UK. 232 patients are expected, some of whom will be recruited from specialist brain tumor centers in the UK.

The exam

Prior to this experiment, an earlier study was done to investigate the safety of combining Sativex with temozolomide. This study is considered a phase I study and recruited 27 patients.

This phase II study will intentionally examine the influence of Sativex and temozolomide on patient survival. The process is called “The Aristocrat Study” and runs for three years. The safety of the phase I regime will also be investigated for a long time.

Professor Short said the initial studies conducted show that the combination of drugs is not only safe, but it can also be the most important step in giving some people extra months or even years if they are lucky. Patients can now look forward to an improved quality of life while living with the disease.

The first study also found that some patients might experience problems with its associated side effects such as nausea, dizziness, and fatigue, but glioblastoma is a devastating disease and any form of drug that gives patients hope is very welcome at this point.

The study is scheduled to begin in 2022. Two-thirds of patients will receive Sativex and temozolomide. The others receive a placebo in addition to the chemotherapeutic agent; Temozolomide.

Financing the process

An estimated £ 450,000 is required to cover the cost of the studies. The Brain Tumor Charity lost 25% of its revenue because the COVID-19 pandemic ended its usual research grant program. It emphasized that the results of the appeal to cover the estimated amount are very important for the start and the success of the procedure.

Dr. David Jenkinson, the interim chief of The Brain Tumor Charity, said the organization hopes the Aristocrat Study would pave the way for the much-needed lengthened lifelines that would help glioblastoma patients live extra months and more memories to gather their family and friends.

Dr. David also expressed the organization’s enthusiasm to be part of the first team to conduct this study – on the potential activity of cannabis drugs in the treatment of brain tumors – worldwide.

Finally

Important studies like these are critical to the future of cancer care. Because they help understand how drugs like cannabis and the chemicals in them can be used to kill aggressive cancer cells or stop them from growing.

Phase I of the study, which was not powered enough to show the magnitude of the effects on survival, showed that patients who received treatment with Sativex plus temozolomide had a higher survival rate than those who received the placebo.

Now imagine how much information can be extracted from the aristocratic degree when all things are in place.

FDA APPROVED BIG PHARMA CANNABIS, READ MORE …

FDA APPROVED CANNABIS SATIVEX

FDA Approved Cannabis Drugs Made in a Lab, Bet You Read This!

OR..

GUIDE TO FDA APPROVED CANNABIS MEDICINE

FDA APPROVED CANNABINOID MEDICINE – THE GUIDE TO WHAT TO GET!

Post a comment:

Your email address will not be published. Required fields are marked *